Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient and tumour characteristics at time of starting trabectedin

From: Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study

Variable N (%)
Age (years), median (IQR) 52 (45–61)
Gender
 Male 29 (37.7)
 Female 48 (62.3)
ECOG performance status
 0 32 (41.6)
 1 43 (55.8)
 2 2 (2.6)
Number of comorbidities
 0 33 (42.9)
 1 19 (24.7)
  ≥ 2 25 (32.4)
Prior history of cancer
 No 68 (88.3)
 Yes 9 (11.7)
Histology
 Leiomyosarcoma 32 (41.6)
 Others 21 (27.2)
 Liposarcoma 14 (18.2)
 Synovial sarcoma 10 (13)
Grade
 I 8 (10.4)
 II 16 (20.8)
 III 27 (35.1)
 Not graded/recorded 28 (36.4)
Site of primary tumour
 Thorax 6 (7.8)
 Abdomen/pelvis 11 (14.3)
 Retroperitoneum 13 (16.9)
 Uterus 21 (27.3)
 Extremity 26 (33.8)
Site of local recurrence (n = 20)
 Thorax 4 (20)
 Abdomen/pelvis 12 (50)
 Retroperitoneum 3 (15)
 Extremity 1 (5)
Site of metastasis (n = 57)
 Brain 1 (1.8)
 Lung 46 (80.7)
 Thorax 4 (7)
 Liver 15 (26.3)
 Abdomen/pelvis 13 (22.8)
 Bone 14 (24.6)
Extent of tumour
 Inoperable primary tumour 13 (16.9)
 Locally recurrent 13 (16.9)
 Recurrent metastatic tumour 44 (57.1)
 Locally recurrent and metastasis 7 (9.1)
  1. ECOG Eastern Cooperative Oncology Group